Blood Cancer Awareness Month (BCAM) – September

Well, here it is! The month that reminds me how lucky I am to have received so much wonderful care thus far in my lymphoma journey. I’m incredibly thankful for all the research which has provided amazing treatments. What we need now, of course, is a cure!! Because it’s Blood Cancer Awareness, we have multiple…… Continue reading Blood Cancer Awareness Month (BCAM) – September

Copanlisib+Rituximab Shows Promise for Some Lymphomas

According to the American Society of Hematology (ASH), findings from phase III of the CHRONOS-3 trial testing a combination therapy using copanlisib and rituximab reduced the risk of progression or death by 48% compared with rituximab alone. The study was open to participants who had relapsed Indolent B-cell Non-Hodgkin’s Lymphoma, including follicular lymphoma, small lymphocytic…… Continue reading Copanlisib+Rituximab Shows Promise for Some Lymphomas

Cutaneous Lymphoma Annual Conference June 18-19

Registration is open for the Cutaneous Lymphoma Foundation’s (CLF) Virtual 2021 Annual Conference, June 18-19. To be clear, the annual conference is real, but it’s being delivered and attended online, i.e. in the virtual world. LOL If you or a loved one are affected by any of the cutaneous lymphomas or lymphomas with expression in…… Continue reading Cutaneous Lymphoma Annual Conference June 18-19

Lacutamab Clinical Trial for Certain CTCL Patients

Innate Pharma has recently announced phase 2 of a clinical trial dubbed TELLOMAK regarding the investigative drug lacutamab (IPH4102), an anti-KIR3DL2 monoclonal antibody, alone or in combination with chemo. The focus of this study is the treatment of patients with the rare cutaneous t-cell lymphoma (CTCL) Mycosis Fungoides and it’s systemic comparable Sézary Syndrome. The…… Continue reading Lacutamab Clinical Trial for Certain CTCL Patients

Blood Cancer and MRD Discussion

After my first successful chemotherapy regimen, I remember the meeting with my oncologist very well. My PET scan came back clear of disease. I was psyched. I was ready to celebrate! But my doctor was surprisingly guarded. Instead of using the word remission (the word I was saying over and over), she chose instead to…… Continue reading Blood Cancer and MRD Discussion